The median progression-free survival was 8.0 months with ipilimumab and 9.6 months without. In patients with unresectable hepatocellular carcinoma (HCC), outcomes with atezolizumab plus bevacizumab ...

Targeting TIGIT with tiragolumab does not improve outcomes over atezolizumab plus bevacizumab in untreated advanced ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

B ERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant ...

Adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improved PFS in patients with platinum-resistant, recurrent ovarian cancer in a phase 3 trial.

El-Khoueiry, MD, an associate professor of clinical medicine in the Division of Medical Oncology and director of the phase I ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.

Black Fern Cheryl Waaka shares her fight against stage four bowel cancer and the family and community support helping her through.